Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Synthetic Peptide Copolymer I

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 154,068Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mapi Pharma Hosts Virtual KOL Event On Glatiramer Acetate
    Mapi Pharma Hosts Virtual KOL Event On Glatiramer Acetate

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3241200/0/en/Mapi-Pharma-to-Host-Virtual-KOL-Event-to-Discuss-Glatiramer-Acetate-Once-a-Month-Depot-for-Primary-Progressive-Multiple-Sclerosis-on-March-3-2026.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Hybio’s Generics Glatiramer Acetate Receives Approval in US
    Hybio’s Generics Glatiramer Acetate Receives Approval in US

    11 Feb 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213382

    FDA
    11 Feb 2026
    Share Share
    Mapi to Present Ph II Data of Long-Acting GA in PPMS at ACTRIMS
    Mapi to Present Ph II Data of Long-Acting GA in PPMS at ACTRIMS

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3231266/0/en/Mapi-Pharma-to-Present-New-Safety-and-Efficacy-Data-from-Glatiramer-Acetate-Depot-Long-Acting-Injection-Phase-II-Study-in-Patients-with-Primary-Progressive-Multiple-Sclerosis-PPMS-.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Scinopharm Gets FDA Nod For Glatiramer Acetate Injection
    Scinopharm Gets FDA Nod For Glatiramer Acetate Injection

    05 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/scinopharm-secures-us-fda-approval-for-glatiramer-acetate-injection-for-the-treatment-of-multiple-sclerosis-302652370.html

    PR NEWSWIRE
    05 Jan 2026
    Share Share
    Zydus receives approval from FDA for Glatiramer Acetate Injection
    Zydus receives approval from FDA for Glatiramer Acetate Injection

    13 May 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/zydus-receives-final-approval-from-usfda-for-glatiramer-acetate-injection-17138

    INDPHARMAPOST
    13 May 2025
    Share Share
    Zydus gets USFDA nod for generic drug to treat multiple sclerosis
    Zydus gets USFDA nod for generic drug to treat multiple sclerosis

    10 May 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-gets-usfda-nod-for-generic-drug-to-treat-multiple-sclerosis/articleshow/121019518.cms

    ECONOMICTIMES
    10 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.